Breast Cancer

Third trastuzumab biosimilar listed on PBS

The trastuzumab biosimilar Kanjinti has been listed on the PBS from 1 December 2019 as an alternative to the originator brand Herceptin for treatment of breast and gastric cancers. Kanjinti becomes the fourth brand of trastuzumab listed on the PBS, after Herceptin  (listed in October 2006) , Ogivri (August 2019) and Herzuma (November 2019). PBS ...

Already a member?

Login to keep reading.

© 2021 the limbic